A Two-part, Randomized, Double-blind, Placebo-controlled, First-In-Human, Phase I Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 Following Administration of Single and Multiple Ascending Oral Doses in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
At a glance
- Drugs SPR 720 (Primary)
- Indications Mycobacterial infections
- Focus Adverse reactions; First in man
- Sponsors Spero Therapeutics
- 29 Jan 2019 According to the Spero Therapeutics media release, top-line results from this trial are expected in the second half of 2019.
- 07 Jan 2019 Status changed from planning to recruiting.
- 08 Nov 2018 According to Spero Therapeutics, trial is expected to start in early 2019.